University of Colorado

Yeda Research and Develpment & Co. Ltd

Ares Trading S.a.

Olatec Therapeutics LLC

Tufts University

Wellesley College

New England Medical Center Hospitals. Inc.

Senesco Technologies, Inc.

Other

Massachusetts Institute of Technology

Virginia Commonwealth University

Ben-gurion University of the Negev Research and Development Authority

Italfarmaco Spa

New England Medical Center

Merck Serono S. A.

Charles A Dinarello

Soo Hyun Kim

Menachem Rubinstein

Daniela Novick

Soo-Hyun Kim

Alexander Rich

Andrew C Webb

Philip E Auron

Eli Chaim Lewis

Soohyun Kim

Sheldon M Wolff

John E Thompson

Lee Gehrke

Lanny J Rosenwasser

Leonid Reznikov

Carlo Marchetti

Yolande Chvatchko

Catherine Taylor

Christine Plater-Zyberk

Peter Gottlieb

Tania Azam

Philip Bufler

James D Crapo

Paolo Mascagni

Leland Shapiro

Dominic O Cliche

Boris Schwartsburd

Gianluca Fossati

Bruce C Galton

Adrienne Boone

Antonio Abbate

Vassilios Kalabokis

Marianne Hopkins

Sheldon M Wolff, Deceased

Peleg Rider

Tanya Azam

Shapiro Leland

Giamila Fantuzzi

Benjamin Pomerantz

Eli C Lewis

Alden Harken

Santer Van Deventer

Daniela Weizmann Institute Of Science Novick

The present invention is directed to a method for treating cardiovascular diseases such as acute myocardial infarction, atherosclerosis, heart failure, stroke, thrombosis, carditis (including acute myocarditis, acute pericarditis and complicated pericarditis), cardiac allograft rejection, cardiomyopathy, and peripheral vascular diseases. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. A preferred route of administration is oral administration.

Methods for treating cardiovascular diseases

Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.

Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides

The present invention is directed to a method for preventing and/or treating melanoma such as superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. The method optionally comprising co-administering anti-PD-1 antibody with dapansutrile. A preferred route of administration is oral administration.

Methods for treating melanoma

The disclosure provides interleukin 37 (IL-37) fusion proteins, methods of making IL-37 fusion proteins including constructs used to express IL-37 fusion proteins, and methods of using IL-37 fusion proteins. In some embodiments, the IL-37 fusion protein includes amino acids 46-206 of isoform B of IL-37 and a heavy chain portion of an antibody.

IL-37 fusion protein and methods of making and using same

The present invention is directed to a method for preventing and/or treating Alzheimer's disease. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. The method reduces neuroinflammation and improves the cognitive functions such as learning and memory processes of the subject. Dapansutrile can be administered to the subject orally at a dose of 100-2000 mg/day for 3 months to 5 years or longer.

Method for preventing or treating Alzheimer's disease

Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantation rejection in the subject. Other embodiments include treating a subject with a composition including AAT before, during or after plastic surgery.

Compositions and methods for preparing a subject for organ or non-organ implantation

The present invention is directed to a method for treating multiple sclerosis by administering dapansutrile to a subject in need thereof. A preferred route of administration is oral administration.

Method for treating multiple sclerosis

Embodiments herein report compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment.

Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Compositions of alpha-1 antitrypsin fusion molecules

The present invention provides a chimera protein made of amino acid residues derived from IL-1beta propeptide and the IL-1Ra mature peptide and polynucleotides encoding the protein. The present invention also provides usages of the protein and the polynucleotides in pharmaceutical compositions that treat inflammation.

IL-1beta propeptide and IL-1Ra chimera and methods of using the same

Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha1-antitrypsin activities.

Compositions and methods related to graft versus host disease and treatments thereof

Embodiments herein report methods and compositions for treating cardiac conditions. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a subject having or suspected of undergoing cardiac remodeling after a cardiac event. Other embodiments herein relate to compounds including naturally occurring and synthetic compositions of alpha-1 antitrypsin and fragments thereof.

Compositions and methods for modulating cardiac conditions

Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantion rejection in the subject. Other embodiments include treating a subject with a composition including AAT before, during or after plastic surgery.

Growing community of inventors

Boulder, CO, United States of America

Charles A Dinarello